BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...billion ($180.6 million). In August, SillaJen Inc. (KOSDAQ:215600) fell 30% after announcing lead program Pexa-Vec pexastimogene devacirepvec...
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

...2, partner Transgene S.A. (Euronext:TNG) said it would stop enrollment in the PHOCUS study of pexa-vec...
...virus failed the interim futility analysis in a Phase III trial to treat liver cancer. Pexa-Vec...
BioCentury | Aug 2, 2019
Clinical News

SillaJen, Transgene fall with latest oncolytic virus setback

...holds North American rights to Pexa-Vec, will likely feel the brunt of the impact as Pexa-Vec...
...told BioCentury the partners would stop enrollment in the Phase III PHOCUS trial of Pexa-Vec pexastimogene devacirepvec...
...Granulocyte macrophage colony-stimulating factor; MUC1 (CD227) - Mucin 1 Lauren Martz, Associate Editor Pexa-Vec, pexastimogene devacirepvec (TG6006, JX-5940TG6006, JX-594) SillaJen...
BioCentury | May 2, 2019
Company News

AstraZeneca adds oncolytic virus option through Transgene deal

...milestones for each product, plus royalties. Details are not disclosed. Transgene's lead program is Pexa-Vec pexastimogene devacirepvec...
BioCentury | Mar 25, 2019
Emerging Company Profile

China Oncology Focus: funding combinations

...China with an oncolytic virus and a checkpoint inhibitor in the clinic. Its virus, Pexa-Vec pexastimogene devacirepvec...
...in the next few months, especially for the combinations,” including a Phase II trial of Pexa-vec...
...AG-013736 (Former compound #), axitinib (Generic), Inlyta (Other) Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) Pexa-Vec, pexastimogene devacirepvec (TG6006, JX-5940TG6006, JX-594) ZKAB001...
BioCentury | Jul 27, 2018
Company News

Lee's mulls spin off, HK IPO for China oncology subsidiary

...will pay Lee's Pharmaceutical (HK) HK$106.5 million ($13.6 million) to acquire Pexa-Vec pexastimogene devacirepvec (JX-594, TG6006, JX-5940TG6006...
...$930,166) to gain melphalan, PARP inhibitor olaparib, imaging agent gliolan and VEGF receptor inhibitor axitinib. Pexa-Vec...
...derivative. Lee's Pharmaceutical Holdings Ltd. (HKSE:950), Hong Kong, China Business: Cancer Sandi Wong Pexa-Vec, pexastimogene devacirepvec (JX-594, TG6006, JX-5940TG6006) Lee's...
BioCentury | Jul 12, 2018
Product R&D

All-in-one viruses

...that a single IV administration of Pexa-Vec pexastimogene devacirepvec selectively acted and replicated in tumor tissues. Pexa-Vec...
...disclose how many patients’ tumors showed evidence of viral infection. “This shows IV administration of Pexa-Vec...
...and academic collaborators noted that in human blood, 90-99% of a vaccinia virus similar to Pexa-Vec...
BioCentury | Dec 1, 2017
Company News

Shenogen, Lee's forge another cancer combo deal

...icaritin, in China to treat late-stage cancer. That combo includes oncolytic virus Pexa-Vec pexastimogene devacirepvec (JX-594, TG6006...
...HKSE:0950), Hong Kong, China Shenogen Pharma Group Ltd., Beijing, China Business: Cancer Elizabeth S. Eaton icaritin companion diagnostic Pexa-Vec Lee's...
BioCentury | Nov 20, 2017
Company News

Shenogen, Lee's forge another cancer combo deal

...icaritin, in China to treat late-stage cancer. That combo includes oncolytic virus Pexa-Vec pexastimogene devacirepvec (JX-594, TG6006...
...of GM-CSF and deletion of thymidine kinase (see BioCentury Extra, Aug. 24, 2016) . Elizabeth S. Eaton icaritin Pexa-Vec SNG-162 Lee's...
BioCentury | Aug 18, 2017
Company News

SillaJen and NCI to evaluate Pexa-Vec with PD-L1 and CTLA-4 antibodies

...cooperative research and development agreement (CRADA) with NIH's National Cancer Institute to evaluate the biotech's Pexa-Vec...
...NCI said trial dates have not yet been set. SillaJen did not respond to inquiries. Pexa-Vec...
...SillaJen Inc. (KOSDAQ:215600), Busan, South Korea National Institutes of Health , Bethesda, Md. Business: Cancer Shannon Lehnbeuter Pexa-Vec National...
Items per page:
1 - 10 of 71